Global Cancer Tumor Profiling Market - Industry Trends and Forecast to 2026

  • Oncology
  • Upcoming Reports
  • Nov 2018
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Cancer Tumor Profiling Market, By Technique (Genomics, Proteomics, Metabolomics, Epigenetics), By Technology (Sequencing Techniques, In Situ Hybridization, Immunohistochemistry, QPCR, Microarray), By Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends & Forecast to 2026

Market Analysis: Global Cancer Tumor Profiling Market

With the rising incidences of cancer cases all over the world, the need for proper screening of Cancer/Tumor is at an all-time high. These profiling methods help in choosing the appropriate course of action and helping determine the effective therapeutics. This trend will attribute to the market witnessing a rise of initial estimated value of USD 11.44 billion in 2018 to an estimated value of USD 22.97 billion by 2026 registering a CAGR of 9.1% in the forecast period of 2019-2026.

Market Definition: Global Cancer Tumor Profiling Market

Cancer/tumor profiling is a diagnostic test that provides genetic information about the cancer or tumor present in the patient’s body. This genetic profiling helps in determining the correct course of action, whether the cancer cells have already metastasized, or when is the cancer most likely to recur again. It also helps in determining the specific therapeutics to aid the patients, and which is most likely to bear the effective results.

Market Drivers:

  • Rising incidences of cancer cases all over the world has increased the demand for Cancer/Tumor profiling which will act as a major market driver
  • The efficient and effective results of these profiling methods will drive the market growth

Market Restraints:

  • High cost of diagnosis and usage of these methods in the treatment is very costly and that will act as a major market restraint
  • Lack of professionals that have the knowledge on the usage of these methods will also act as a restraint for the market growth

Segmentation: Global Cancer Tumor Profiling Market

  • By Technique

    • Genomics
    • Proteomics
    • Metabolomics
    • Epigenetics

  • By Technology

    • Sequencing Techniques

      • Next Generation Sequencing
      • Sanger Sequencing
      • Pyro Sequencing

    • In Situ Hybridization
    • Immunohistochemistry
    • Quantitative Polymerase Chain Reaction (QPCR)
    • Microarray

  • By Application

    • Personalized Medicine
    • Diagnostics
    • Biomarker Discovery
    • Prognostics
    • Research Applications

  • By Cancer Type

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma Cancer
    • Others

      • Non-Hodgkin’s Lymphoma
      • Melanoma
      • Leukemia
      • Thyroid
      • Bladder
      • Kidney

  • By Geography

    • North America

      • US
      • Canada
      • Mexico

    • South America

      • Brazil
      • Argentina
      • Rest of South America

    • Europe

      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe

    • Asia-Pacific

      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific

    • Middle East and Africa

      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East and Africa

Competitive Analysis: Global Cancer Tumor Profiling Market

The global cancer/tumor profiling market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Cancer/Tumor Profiling market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Research Methodology: Global Cancer Tumor Profiling Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Key Market Competitors: Global Cancer Tumor Profiling Market

Few of the major market competitors currently working in the Cancer/Tumor Profiling Market are Illumina Inc., QIAGEN, NeoGenomics Laboratories Inc., HTG Molecular Diagnostics, Genomic Health, Caris Life Sciences, Helomics Corp, NanoString Technologies Inc., Oxford Gene Technology IP Limited, Ribomed, F. Hoffmann-La Roche Ltd, Abbott, Hologic Inc., BD, Siemens Healthcare GmbH, Claris Lifesciences Ltd., Personal Genome Diagnostics Inc., Perthera Inc., FOUNDATION MEDICINE INC., Precision Medicine Group Inc., Contextual Genomics, Agendia, GenScript, NanoString Technologies Inc., GenomeDx, and GUARDANT HEALTH INC.

Key Insights in the report:

  • The key market players are analyzed and their effects on the market is also observed
  • Market analysis is conducted for the forecast period of 2019 to 2026, and the market segmentations are observed during that period
  • The market drivers and restraints have been clearly analyzed for the effect that they have over the market in the forecast period of 2019 to 2026

SKU-

TABLE OF CONTENTS GLOBAL CANCER TUMOR PROFILING MARKET

1. INTRODUCTION

1.1 OVERVIEW OF THE GLOBAL CANCER TUMOR PROFILING MARKET
1.2 CURRENCY AND PRICING
1.3 LIMITATION
1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL CANCER TUMOR PROFILING MARKET

2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CANCER TUMOR PROFILING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 RISING INCIDENCES OF CANCER PATIENT
3.1.2 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCH
3.1.3 RISING GOVERNMENT INITIATIVES AND AVAILABILITY OF FUNDING FOR CANCER RESEARCH
3.1.4 INCREASE IN THE USE OF BIOMARKERS IN TUMOR PROFILING

3.2 RESTRAINTS

3.2.1 LACK OF OF WELL-TRAINED AND EXPERIENCED PROFESSIONALS
3.2.2 HIGH MONETARY INVESTMENTS AND LOW BENEFIT RATIO FOR BIOMARKERS AND BIOSIMILAR
3.3 OPPORTUNITIES
3.3.1 RISING DEMAND FOR PERSONALIZED MEDICINE
3.3.2 INNOVATION OF POINT-OF-CARE & MINIATURIZED DIAGNOSTIC DEVICES
3.4 CHALLENGES
3.4.1 STRINGENT REGULATORY PROCEDURE AND REIMBURSEMENT POLICIES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL CANCER TUMOR PROFILING MARKET, BY TECHNOLOGY

6.1 OVERVIEW
6.2 NEXT-GENERATION SEQUENCING
6.3 QUANTITATIVE POLYMERASE CHAIN REACTION
6.4 IMMUNOHISTOCHEMISTRY
6.5 IN SITU HYBRIDIZATION
6.5.1 FLUORESCENCE IN SITU HYBRIDIZATION
6.5.2 CHROMOGENIC IN SITU HYBRIDIZATION
6.6 MICROARRAY
6.7 FRAGMENT ANALYSIS

7 GLOBAL CANCER TUMOR PROFILING MARKET, BY TECHNIQUE

7.1 OVERVIEW
7.2 GENOMICS
7.3 PROTEOMICS
7.4 EPIGENETICS
7.5 METABOLOMICS

8 GLOBAL CANCER TUMOR PROFILING MARKET, BY APPLICATION

8.1 OVERVIEW
8.2 PERSONALIZED MEDICINE
8.3 DIAGNOSTICS
8.4 BIOMARKER DISCOVERY
8.5 PROGNOSTICS
8.6 RESEARCH APPLICATIONS

9 GLOBAL CANCER TUMOR PROFILING MARKET, BY COUNTRY

9.1 GLOBAL CANCER TUMOR PROFILING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

9.1.1 NORTH AMERICA

9.1.1.1 U.S.
9.1.1.2 CANADA
9.1.1.3 MEXICO

9.1.2 EUROPE

9.1.2.1. GERMANY
9.1.2.2 FRANCE
9.1.2.3 U.K.
9.1.2.4 ITALY
9.1.2.5 SPAIN
9.1.2.6 RUSSIA
9.1.2.7 TURKEY
9.1.2.8 BELGIUM
9.1.2.9 NETHERLANDS
9.1.2.10 SWITZERLAND
9.1.2.11 REST OF EUROPE

9.1.3 ASIA-PACIFIC (APAC)

9.1.3.1 JAPAN
9.1.3.2 CHINA
9.1.3.3 SOUTH KOREA
9.1.3.4 INDIA
9.1.3.5 AUSTRALIA
9.1.3.6 SINGAPORE
9.1.3.7 THAILAND
9.1.3.8 MALAYSIA
9.1.3.9 INDONESIA
9.1.3.10 PHILIPPINES
9.1.3.11 REST OF APAC

9.1.4 SOUTH AMERICA

9.1.4.1 BRAZIL
9.1.4.2 REST OF LATIN AMERICA

9.1.5 MIDDLE EAST AND AFRICA

9.1.5.1 SAUDI ARABIA
9.1.5.2 SOUTH AFRICA
9.1.5.3 REST OF MIDDLE EAST AND AFRICA
9.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

10 GLOBAL CANCER TUMOR PROFILING MARKET: COMPETITIVE LANDSCAPE

10.1. GLOBAL CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.2. NORTH AMERICA CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.4. APAC CANCER TUMOR PROFILING MARKET: COMPANY SHARE ANALYSIS
10.5. MERGERS & ACQUISITIONS
10.6. NEW PRODUCT DEVELOPMENT & APPROVALS
10.7. EXPANSIONS
10.8. REGULATORY CHANGES
10.9. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

11 GLOBAL CANCER TUMOR PROFILING MARKET, COMPANY PROFILES

11.1 ILLUMINA, INC.

11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL ANALYSIS
11.1.3 PRODUCT MATRIX
11.1.4 RECENT DEVELOPMENTS
11.1.5 DATABRIDGE ANALYSIS

11.2 QIAGEN

11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL ANALYSIS
11.2.3 PRODUCT MATRIX
11.2.4 RECENT DEVELOPMENTS
11.2.5 DATABRIDGE ANALYSIS

11.3 F. HOFFMANN-LA ROCHE LTD

11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL ANALYSIS
11.3.3 PRODUCT MATRIX
11..3.4 RECENT DEVELOPMENTS
11.3.5 DATABRIDGE ANALYSIS

11.4 HTG MOLECULAR DIAGNOSTICS, INC.

11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL ANALYSIS
11.4.3 PRODUCT MATRIX
11.4.4 RECENT DEVELOPMENTS
11.4.5 DATABRIDGE ANALYSIS

11.5 GENOMIC HEALTH

11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL ANALYSIS
11.5.3 PRODUCT MATRIX
11.5.4 RECENT DEVELOPMENTS
11.5.5 DATABRIDGE ANALYSIS

11.6 CARIS LIFE SCIENCES

11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL ANALYSIS
11.6.3 PRODUCT MATRIX
11.6.4 RECENT DEVELOPMENTS
11.6.5 DATABRIDGE ANALYSIS

11.7 HELOMICS CORP.

11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL ANALYSIS
11.7.3 PRODUCT MATRIX
11.7.4 RECENT DEVELOPMENTS
11.7.5 DATABRIDGE ANALYSIS

11.8 NANOSTRING TECHNOLOGIES, INC.

11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL ANALYSIS
11.8.3 PRODUCT MATRIX
11.8.4 RECENT DEVELOPMENTS
11.8.5 DATABRIDGE ANALYSIS

11.9 OXFORD GENE TECHNOLOGY

11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL ANALYSIS
11.9.3 PRODUCT MATRIX
11.9.4 RECENT DEVELOPMENTS
11.9.5 DATABRIDGE ANALYSIS

11.10 ABBOTT

11.10.1 COMPANY OVERVIEW
11. 10.2 FINANCIAL ANALYSIS
11. 10.3 PRODUCT MATRIX
11.10.4 RECENT DEVELOPMENTS
11.10.5 DATABRIDGE ANALYSIS

11.11 HELOMICS CORP.

11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL ANALYSIS
11.11.3 PRODUCT MATRIX
11.11.4 RECENT DEVELOPMENTS
11.11.5 DATABRIDGE ANALYSIS

11.12 GENSCRIPT

11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL ANALYSIS
11.12.3 PRODUCT MATRIX
11.12.4 RECENT DEVELOPMENTS
11.12.5 DATABRIDGE ANALYSIS

11.13 RIBOMED

11.13.1 COMPANY OVERVIEW
11.13.2 FINANCIAL ANALYSIS
11.13.3 PRODUCT MATRIX
11.13.4 RECENT DEVELOPMENTS
11.13.5 DATABRIDGE ANALYSIS

11.14 HOLOGIC, INC.

11.14.1 COMPANY OVERVIEW
11.14.2 FINANCIAL ANALYSIS
11.14.3 PRODUCT MATRIX
11.14.4 RECENT DEVELOPMENTS
11.14.5 DATABRIDGE ANALYSIS

11.15 BOREAL GENOMICS INC.

11.15.1 COMPANY OVERVIEW
11.15.2 FINANCIAL ANALYSIS
11.15.3 PRODUCT MATRIX
11.15.4 RECENT DEVELOPMENTS
11.15.5 DATABRIDGE ANALYSIS

11.16 PERTHERA, INC.

11.16.1 COMPANY OVERVIEW
11.16.2 FINANCIAL ANALYSIS
11.16.3 PRODUCT MATRIX
11.16.4 RECENT DEVELOPMENTS
11.16.5 DATABRIDGE ANALYSIS

11.17 NEOGENOMICS LABORATORIES, INC.

11.17.1 COMPANY OVERVIEW
11.17.2 FINANCIAL ANALYSIS
11.17.3 PRODUCT MATRIX
11.17.4 RECENT DEVELOPMENTS
11.17.5 DATABRIDGE ANALYSIS

12 APPENDIX

13 ABOUT DATA BRIDGE MARKET RESEARCH

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART